Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)
20 nov. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)
18 nov. 2019 08h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Reports Q3 2019 Pipeline Update
08 nov. 2019 07h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos continued...
Seelos Therapeutics to Participate in Upcoming Investor Conferences in December
01 nov. 2019 10h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd...
Seelos Therapeutics Announces Amendment of SLS-002 Agreement
21 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
Seelos Plans to Study SLS-002 Initially in Suicidality in Major Depressive Disorder NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage...
Seelos Therapeutics to Participate in Upcoming Investor Conference in November
18 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019...
Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
15 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...
Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering
23 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase...
Seelos Therapeutics Reports Q2 2019 Pipeline Update
01 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, today released its second quarter pipeline update. “We have made...
Breakthrough Clinical Trial to be featured on CNN: Reductions in Suicidality, Depression, and Post-Traumatic Stress
10 nov. 2016 19h00 HE
|
MYnd Analytics, Inc.
MISSION VIEJO, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. ("MYnd") (OTCQB:MYAN), announces publication of “The Use of the Psychiatric Electroencephalography Evaluation Registry...